Neurology · Medical Literature
Genome wide association study meta-analysis of neuropathologic lesions of Alzheimer's disease and related dementias in a multi-site autopsy cohort.
Abstract
Understanding the genetic foundations of dementia is critical to unraveling its complex molecular basis. Given that a clinical diagnosis of Alzheimer's disease (AD) dementia often results from interplay between multiple underlying neuropathologic co-morbidities, previous genome-wide association studies (GWAS) of clinically diagnosed AD are restricted in their ability to translate genetic associations to potential targeted therapeutics. The current study seeks to address these limitations by presenting the largest GWAS to date (n = 12,509) of neuropathologic hallmarks of AD and AD related dementias (ADRDs). We further performed a candidate-variant analysis using loci previously identified in GWAS of clinically diagnosed AD dementia and Parkinson's disease (PD). Finally, we conducted heritability and genetic correlation analyses using linkage disequilibrium (LD) score regression. We found broad genome-wide significant associations with APOE across AD and ADRDs but not cerebrovascular disease and vascular brain injury. We further identified 12 significant loci across 10 neuropathologic phenotypes, including 5 loci previously implicated in GWAS of clinical AD and ADRDs (variants on BIN1, PICALM/ EED, TMEM106B, GRN, and SNCA/ SNCA-AS1) and 7 novel genome-wide associations (variants on EPHA5, PSMG1, LINC00276, VAPA, LINC00290, DOCK4 and SLAIN2/ SLC10A4). Our analysis of AD and PD clinical candidate variants demonstrated several that were associated with AD neuropathologic change and Lewy body disease, as well as substantial overlap with neuropathologic lesions other than the primary neuropathologic hallmarks of these diseases. Heritability analyses demonstrated heritability that was high for amyloid plaques (78%) relative to prior clinical AD heritability analyses, intermediate for TDP-43 inclusions (41%), and low for remaining AD and ADRD pathologic features. This study underscores the importance of investigating the underlying neuropathologic hallmarks of AD and ADRDs as a step toward refining the translation of genetic associations to biomarker interpretation and development of targeted therapeutics.
Clinical relevance
In the largest autopsy-based GWAS to date, which genetic loci are associated with specific neuropathologic hallmarks of Alzheimer's disease (AD) and AD-related dementias (ADRDs), and how do these associations differ from those identified in clinical-diagnosis-based GWAS? __SNAPSHOT__ {"studyDesign":"GWAS meta-analysis with candidate-variant analysis and SNP heritability/genetic correlation analyses (LD score regression); cross-sectional neuropathologic endophenotype study using multi-site brain autopsy data","setting":"Multi-site autopsy cohort; data harmonized through the Alzheimer's Disease Genetics Consortium (ADGC); institutions include University of Washington, University of Miami, University of Pennsylvania, Vanderbilt University, Columbia University, and others across the United States","sampleSize":"n = 12,509 (total harmonized neuropathologic and genetic sample; per-phenotype sub-cohort sizes not reported in abstract)","population":"Brain autopsy donors with research-quality neuropathologic and genetic data; neuropathologic phenotypes included AD neuropathologic change (ADNC: neurofibrillary tangles [NFTs], neuritic plaques [NPs], amyloid plaques [APs]), cerebral amyloid angiopathy (CAA), Lewy body disease (LBD), hippocampal sclerosis (HS), TDP-43 proteinopathy (LATE-NC), cerebrovascular disease (CBVD), and vascular brain injury (VBI); ancestry composition not detailed in abstract","intervention":"Genome-wide association study of neuropathologic lesion severity/presence as primary phenotypes (endophenotype-based GWAS); supplemented by candidate-variant analysis of known clinical AD and Parkinson's disease (PD) GWAS loci","comparator":"Not applicable (single-cohort GWAS; results compared contextually to prior clinical-diagnosis-based GWAS literature)","primaryOutcome":"Genome-wide significant (p < 5×10⁻⁸) genetic associations with individual neuropathologic hallmarks of AD and ADRDs assessed by current consensus neuropathologic protocols","followUp":"Not applicable (cross-sectional autopsy data); age at death and sex used as covariates","fundingSource":"Not reported in abstract; study conducted under the ADGC framework, which is typically supported by National Institute on Aging (NIA) grants"}
Key findings
The study identified genome-wide significant (GWS) APOE associations across multiple AD and ADRD neuropathologic phenotypes. Specifically, APOE reached GWS for NFTs, NPs, APs, CAA, LBD, HS, and TDP-43 proteinopathy, but notably not for cerebrovascular disease (CBVD) or vascular brain injury (VBI), after adjustment for age at death and sex. Beyond APOE, 12 significant loci across 10 neuropathologic phenotypes were identified. Of these, 5 loci were previously implicated in clinical AD or ADRD GWAS: BIN1 (top SNP rs6733839; minimum p for NPs = 1.6×10⁻¹³, minimum p for NFTs = 1.4×10⁻¹⁶), PICALM/EED (associated with NPs), TMEM106B, GRN, and SNCA/SNCA-AS1. Seven loci were novel genome-wide associations: EPHA5, PSMG1, LINC00276, VAPA, LINC00290, DOCK4, and SLAIN2/SLC10A4. Effect sizes for BIN1 top variants were similar for NPs and NFTs. Candidate-variant analysis of known clinical AD and PD GWAS loci demonstrated substantial overlap with multiple ADNC and ADRD neuropathologic lesions beyond each disease's primary hallmarks, indicating cross-pathology genetic pleiotropy. SNP heritability analyses (APOE region excluded; liability scale) showed high heritability for amyloid plaques (h² = 0.78), intermediate heritability for TDP-43 inclusions (h² = 0.41), and low heritability (h² < 0.20) for remaining ADRD pathologic features including LBD, CBVD, and VBI. Individual-variant effect sizes, confidence intervals, odds ratios, NNT/NNH, and formal p-values beyond those noted above were not reported in the available abstract; full quantitative data are in the published tables. NNT/NNH: not calculable from reported data.
Practice implications
This study established that the genetic architecture of dementia-associated brain pathology is partially distinct from that uncovered by clinical-diagnosis GWAS, confirming that endophenotype-based approaches can resolve disease-specific genetic signals obscured by diagnostic syndromic lumping. APOE's influence on most proteinopathies (but not cerebrovascular or vascular injury phenotypes) is an important finding suggesting that APOE-targeted interventions may not benefit patients whose dementia is primarily vascular in etiology. The 7 novel loci (EPHA5, PSMG1, LINC00276, VAPA, LINC00290, DOCK4, SLAIN2/SLC10A4) are hypothesis-generating for future functional studies and potential therapeutic target prioritization, but cannot be directly translated to clinical practice without replication and functional validation. Candidate-variant analysis revealing cross-pathology pleiotropy underscores that many 'AD genes' may exert risk partly through non-amyloid, non-tau mechanisms, which is critically relevant to interpreting biomarker studies and trial enrichment strategies. The high SNP heritability of amyloid plaques (78%) versus the lower heritability of vascular and other ADRD lesions suggests differential genetic versus environmental determinism across dementia subtypes. Findings apply to autopsy-ascertained research cohorts; living patients, those without autopsy data, and non-European ancestry groups (if underrepresented in ADGC) are not adequately represented. This is a full-length published open-access article (PLoS Genetics, June 2026), not abstract-only, though this summary is based on the abstract and supplemental excerpts; full methods, cohort-specific breakdowns, and complete effect size tables are available in the primary publication. __LIMITATIONS__ Sample size (n = 12,509), while the largest autopsy GWAS to date, remains substantially smaller than clinical-diagnosis GWAS exceeding one million individuals, limiting power to detect variants with modest effect sizes and reducing the ability to distinguish true non-association from underpowering.,Fixed-effects meta-analysis was used to maximize power; effect-size heterogeneity across contributing sites and genotyping arrays is a potential concern, though genome-wide heterogeneity statistics did not broadly support this.,Autopsy ascertainment bias: research volunteer cohorts may not represent the general dementia population; differential survival, referral patterns, and willingness to donate may skew neuropathologic phenotype distributions.,Ancestry composition of the cohort is not detailed in the abstract; if predominantly of European descent, findings may have limited generalizability to other populations.,Multiple testing in candidate-variant analyses: the correction strategy for candidate-variant sub-analyses requires scrutiny, as the authors acknowledge this is a potential limitation.,Heritability and genetic correlation estimates are likely imprecise given the relatively small sample size, and the authors themselves flag the need for confirmation studies.,Neuropathologic phenotype harmonization across sites introduces potential misclassification, particularly for lesions with evolving consensus criteria (e.g., LATE-NC, LBD staging).,No functional validation of the 7 novel loci; biological mechanisms are unknown.,Funding source not reported, limiting full assessment of potential conflicts of interest.,Cross-sectional design precludes causal inference; temporal sequence of genetic effects on lesion accumulation cannot be established. __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ This largest-to-date autopsy GWAS (n = 12,509) confirms APOE's broad association with proteinopathic but not cerebrovascular dementia lesions, identifies 5 known and 7 novel genetic loci mapped to specific neuropathologic endophenotypes, and demonstrates that many clinical AD GWAS loci exert effects across multiple ADRD pathologies. These findings do not alter current clinical practice but substantially refine the genetic roadmap for biomarker development and targeted therapeutic discovery in dementia, and argue for routine neuropathologic endophenotyping in future genetic studies.